Richard William Scalzo

CIK 1789545 · Chief Financial Officer · last filed 2025-12-17

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.23M

Companies

2

Total Filings

36

Lifetime Open-Market Net

-$8.71M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CRESCENT BIOPHARMA, INC. (GLYC) Delisted Chief Financial Officer 19,422 $15.70 $304.9K $0 1 2025-12-17
DYN SVP, Head of Finance & Admin. 122,330 $18.19 $2.23M -$8.71M 35 2025-03-13

Recent Filings · Page 3 of 4

36 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2023-12-06 DYN Sell (S) −2,553 -$30.7K EDGAR
2023-11-16 DYN Grant (A) +89,742 $0 EDGAR
2023-09-20 DYN Sell (S) −1,290 -$12.1K EDGAR
2023-09-13 DYN Sell (S) −1,397 -$14.5K EDGAR
2023-06-15 DYN Mixed −11,390 -$612.0K EDGAR
2023-03-15 DYN Sell (S) −1,311 -$17.5K EDGAR
2022-12-13 DYN Mixed +30,688 -$3.4K EDGAR
2022-09-21 DYN Disp (D) −840 -$11.5K EDGAR
2022-09-15 DYN Disp (D) −326 -$4.6K EDGAR
2022-07-13 DYN Grant (A) $0 EDGAR
Showing 2130 of 36
Page 3 of 4
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.